About Us

Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April

By: via Benzinga
TESARO Inc (NASDAQ: TSRO) announced the FDA approval of Zejula (niraparib) in recurrent ovarian cancer maintenance with a broad label. ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.